VIVUS, Inc. (VVUS)
(Delayed Data from NSDQ)
$3.73 USD
+0.03 (0.81%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.83 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.73 USD
+0.03 (0.81%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.83 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has decided to stay outstanding litigation and extend the 30-month stay regarding Teva's ANDA for a generic version of Xifaxan 550 mg tablets.
Incyte (INCY) Announces Positive Data on Enzyme Inhibitor
by Zacks Equity Research
Incyte Corporation (INCY) recently announced that new data was published from the ongoing trial, ECHO-202 online by the American Society of Clinical Oncology (ASCO).
J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021
by Zacks Equity Research
Johnson & Johnson, Inc. (JNJ) discussed its future plans and showcased a strong pipeline of transformational medicines at a meeting held yesterday with industry analysts.
Concert Pharma Falls After Clinical Hold on Hair Loss Drug
by Zacks Equity Research
Concert Pharmaceuticals, Inc. (CNCE) shares were down almost 8% on Wednesday after the company announced that the FDA has placed a clinical hold on a mid-stage study evaluating its pipeline candidate CTP-543 for the treatment of alopecia areata.
Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated???s (VRTX) announced that the FDA has approved its lead marketed drug, Kalydeco (ivacaftor) for expanded use.
Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status
by Zacks Equity Research
Sangamo Therapeutics, Inc. (SGMO) announced that the FDA has granted fast track designation to pipeline candidate, SB-525.
Alexion's (ALXN) Strensiq Results Positive in Long-Term Study
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) announced that researchers presented encouraging data on Strensiq at the European Calcified Tissue Society (ECTS) Congress in Austria.
Kamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Kamada Ltd. (KMDA) reported adjusted loss of 11 cents in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 3 cents.
Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth
by Zacks Equity Research
On May 16, we issued an updated research report on La Jolla, CA based Orexigen Therapeutics, Inc. (OREX). Orexigen is a biopharmaceutical company focused on the development of obesity treatments.
Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Cardiome Pharma Corp. (CRME) reported loss of 20 cents per share in first quarter of 2017. Reported loss is wider than both the Zacks Consensus Estimate of a loss of 15 cents and year-ago loss of 9 cents.
Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now
by Zacks Equity Research
On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI).
Celgene's (CELG) Revlimid Looks Solid on Label Expansion
by Zacks Equity Research
Celgene's key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration.
Aerie's (AERI) Rhopressa NDA Sufficient for FDA Review
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) announced that it has received notification from the FDA about the completion of the initial 60-day review of the NDA for Rhopressa
Minerva (NERV) Provides Phase III Development Strategy for MIN-101
by Zacks Equity Research
Minerva Neurosciences, Inc. (NERV) announced plans for its phase III and phase IV clinical development of pipeline candidate MIN-101.
Ionis (IONS) Stock Falls Despite Positive Inotersen Data
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) announced that the phase III study NEURO-TTR on inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.
Why Is Vertex Pharma (VRTX) Stock Soaring This Year?
by Zacks Equity Research
Vertex Pharmaceuticals, Inc.'s (VRTX) shares have risen 57.8% this year so far, outperforming the increase of 1.3% for the Zacks classified Large-Cap Pharma industry.
BioDelivery (BDSI) Q1 Earnings Beat Estimates, Stock Gains
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) reported earnings of 58 cents per share in the first quarter of 2017, which comfortably beat the Zacks Consensus Estimate of 9 cents.
Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q4
by Zacks Equity Research
Dr. Reddy's Laboratories Ltd. (RDY) reported fourth-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 29 cents, down from 7 cents in the year-ago quarter.
AbbVie and J&J Present Positive Imbruvica Leukemia Data
by Zacks Equity Research
AbbVie Inc. (ABBV) recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib).
Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1
by Zacks Equity Research
Nektar Therapeutics (NKTR) reported first-quarter 2017 loss of 42 cents per share, wider than the Zacks Consensus Estimate of a loss of 40 cents.
Inovio (INO) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) reported loss of 31 cents for the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 34 cents.
Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales
by Zacks Equity Research
Jazz Pharmaceuticals Public Limited Company (JAZZ) reported first-quarter 2017 earnings of $1.41 per share, which narrowly missed the Zacks Consensus Estimate of $1.42.
Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) reported first-quarter 2017 adjusted loss of 33 cents per share, significantly wider than both the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 8 cents.
Mallinckrodt Earnings, Revenues Beat Estimates in Q1
by Zacks Equity Research
Mallinckrodt Public Limited Company (MNK) reported first-quarter 2017 results wherein both sales and earnings beat expectations.
ImmunoGen (IMGN) Posts Narrower-than-Expected Loss in Q1
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) reported a loss of 20 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of 36 cents and the year-ago loss of 37 cents.